TrioxBio Announces Fast Track Designation Granted by U.S. FDA to Raviten® for the Treatment of Intradialytic Hypotension
Phase II clinical trials in patients undergoing hemodialysis to be initiated in Q4, 2018 TrioxBio Inc., a clinical-stage biopharmaceutical company specializing in the development of drugs to treat diseases and medical conditions related to the pathological overproduction of nitric oxide (NO), today announced that the U.S.… Read More